Category Archives: Cancer Treat Rev

Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer – ESMO-MCBS scores.

Related Articles

Clinical benefit of controversial first line systemic therapies for advanced stage ovarian cancer – ESMO-MCBS scores.

Cancer Treat Rev. 2018 Jun 18;69:233-242

Authors: Broekman KE, Jalving M, van Tinteren H, Sessa C, Reyners AKL

Abstract
BACKGROUND: The magnitude of clinical benefit scale (MCBS) was introduced by the European Society of Medical Oncology (ESMO) to quantify the clinical benefit of therapeutic regimens and to prioritise therapies. It distinguishes curative from palliative treatments and ranks their benefit based on overall survival (OS), progression free survival (PFS), quality of life (QoL) and toxicity. Objective of this study on the first line treatment of ovarian cancer was to evaluate the evidence for the current standard of care using the ESMO-MCBSv1.1 with an emphasis on controversial therapeutic options: intraperitoneal chemotherapy, dose-dense paclitaxel and bevacizumab.
METHODS: Phase III trials, published since 1992, investigating first line systemic treatment of Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) stage IIB-IV epithelial ovarian cancer were included. Since most studies included patients with FIGO stage IV disease or incomplete debulking, all treatments were judged to be palliative. Treatments were graded 5 to 1 on the ESMO-MCBSv1.1, where grades 5 and 4 represent a high level of clinical benefit.
RESULTS: 55 studies met the inclusion criteria. ESMO-MCBS scores were calculated for eleven studies that showed a statistically significant benefit of the experimental treatment. Intraperitoneal (ip) cisplatin scored a 4 and 3, but two other studies were negative and therefore not scored on the ESMO-MCBS. Dose-dense paclitaxel showed substantial clinical benefit in one study (score 4), but three studies were negative. Addition of bevacizumab also scored a 4 in one study subgroup including high-risk patients but a 2 in another trial with a larger study population.
CONCLUSION: Based on ESMO-MCBS scores, dose-dense paclitaxel and intraperitoneal chemotherapy cannot be recommended as standard treatment. Bevacizumab should be considered only in the high-risk population. The ESMO-MCBSv1.1. helps to summarise reported studies on controversial treatment regimens, and identifies their weaknesses.

PMID: 30098485 [PubMed – as supplied by publisher]

Continue reading

Posted in Cancer Treat Rev | Tagged , | Leave a comment

Is there a relation between type of primary melanoma treatment and the development of intralymphatic metastasis? A review of the literature.

Is there a relation between type of primary melanoma treatment and the development of intralymphatic metastasis? A review of the literature.
Cancer Treat Rev. 2016 Mar 2;45:120-128
Authors: Sloot S, Speijers MJ, Bast… Continue reading

Posted in Cancer Treat Rev | Tagged | Leave a comment

Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma – A systematic review.

Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma – A systematic review.
Cancer Treat Rev. 2015 Sep 10;
Authors: Clement SC, Peeters RP, Ronckers CM, Links TP, van… Continue reading

Posted in Cancer Treat Rev | Leave a comment

Rectal and colon cancer: Not just a different anatomic site.

Rectal and colon cancer: Not just a different anatomic site.
Cancer Treat Rev. 2015 Jun 28;
Authors: Tamas K, Walenkamp AM, de Vries EG, van Vugt MA, Beets-Tan RG, van Etten B, de Groot DJ, Hospers GA
Abstrac… Continue reading

Posted in Cancer Treat Rev | Leave a comment

Cancer-drug induced insulin resistance: Innocent bystander or unusual suspect.

Cancer-drug induced insulin resistance: Innocent bystander or unusual suspect.
Cancer Treat Rev. 2015 Feb 18;
Authors: Ariaans G, de Jong S, Gietema JA, Lefrandt JD, de Vries EG, Jalving M
Abstract
Ep… Continue reading

Posted in Cancer Treat Rev | Leave a comment

Assessing treatment effects in older breast cancer patients: Systematic review of observational research methods.

Related Articles
Assessing treatment effects in older breast cancer patients: Systematic review of observational research methods.
Cancer Treat Rev. 2015 Jan 10;
Authors: de Glas NA, Kiderlen M, de Craen AJ, Hamaker M… Continue reading

Posted in Cancer Treat Rev | Tagged | Leave a comment

Is outcome of differentiated thyroid carcinoma influenced by tumor stage at diagnosis?

Is outcome of differentiated thyroid carcinoma influenced by tumor stage at diagnosis?
Cancer Treat Rev. 2015 Jan;41(1):9-16
Authors: Clement SC, Kremer LC, Links TP, Mulder RL, Ronckers CM, van Eck-Smit BL, van Rijn… Continue reading

Posted in Cancer Treat Rev | Leave a comment

Metallic taste in cancer patients treated with chemotherapy.

Metallic taste in cancer patients treated with chemotherapy.
Cancer Treat Rev. 2014 Dec 5;
Authors: IJpma I, Renken RJ, Ter Horst GJ, Reyners AK
Abstract
BACKGROUND: Metallic taste is a taste alterati… Continue reading

Posted in Cancer Treat Rev | Leave a comment

Surgical emergencies in oncology.

Related Articles
Surgical emergencies in oncology.
Cancer Treat Rev. 2014 Sep;40(8):1028-36
Authors: Bosscher MR, van Leeuwen BL, Hoekstra HJ
Abstract
An oncologic emergency is defined as an acute, po… Continue reading

Posted in Cancer Treat Rev | Leave a comment

Patients’ preferences for surgical and adjuvant systemic treatment in early breast cancer: A systematic review.

Related Articles
Patients’ preferences for surgical and adjuvant systemic treatment in early breast cancer: A systematic review.
Cancer Treat Rev. 2014 Jun 23;
Authors: Hamelinck VC, Bastiaannet E, Pieterse AH, Jannin… Continue reading

Posted in Cancer Treat Rev | Tagged | Leave a comment

Management of fatigue in patients with cancer — a practical overview.

Related Articles

Management of fatigue in patients with cancer — a practical overview.

Cancer Treat Rev. 2014 Jul;40(6):791-9

Authors: Koornstra RH, Peters M,…

Continue reading

Posted in Cancer Treat Rev | Tagged | Leave a comment

Age and the effect of physical activity on breast cancer survival: A systematic review.

Related Articles
Age and the effect of physical activity on breast cancer survival: A systematic review.
Cancer Treat Rev. 2013 Dec;39(8):958-65
Authors: Fontein DB, de Glas NA, Duijm M, Bastiaannet E, Portielje JE, Van de Vel… Continue reading

Posted in Cancer Treat Rev | Tagged | Leave a comment

Isolated limb perfusion of soft tissue sarcomas: a comprehensive review of literature.

Related Articles

Isolated limb perfusion of soft tissue sarcomas: a comprehensive review of literature.

Cancer Treat Rev. 2013 Oct;39(6):569-77

Authors: Seinen JM,…

Continue reading

Posted in Cancer Treat Rev | Tagged | Leave a comment

Hypoxia imaging using Positron Emission Tomography in non-small cell lung cancer: implications for radiotherapy.

Related Articles
Hypoxia imaging using Positron Emission Tomography in non-small cell lung cancer: implications for radiotherapy.
Cancer Treat Rev. 2012 Dec;38(8):1027-32
Authors: Bollineni VR, Wiegman EM, Pruim J, Groen HJ, L… Continue reading

Posted in Cancer Treat Rev | Tagged , | Leave a comment